Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: A prospective randomized study of the Southern Italy Oncology Group (GOIM)

British Journal of Cancer

Volumn 76, Issue 11, 1997, Pages 1509-1517

  Colucci, G ^a   Gebbia, V ^b,e   Galetta, D ^a   Riccardi, F ^c   Cariello, S ^d   Gebbia, N ^b   Durini, Ernesto ^f   Scoditti, Salvatore ^g   Toma, Pasquale ^g   Lorenzo, Roberto ^g   Pandolfo, Giuseppe ^h   Pezzella, Giuseppe ⁱ  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

^d Ospedale S Leonardo   (Italy)

^e Institute of Pharmacology   (Italy)

^f Division of Internal Medicine   (Italy)

^g Hospital 'Galateo'   (Italy)

^h Hospital 'San Biagio'   (Italy)

ⁱ Azienda Ospedaliera 'SS Annunziata'   (Italy)

Author keywords

Chemotherapy; Cisplatin; Day's worst drug rule; Epirubicin; Ifosfamide; Lung cancer; Vinorelbine

Indexed keywords

CISPLATIN; EPIRUBICIN; IFOSFAMIDE; MESNA; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ITALY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMATITIS; VOMITING;

EID: 9844229899     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.586     Document Type: Article

References (35)

1. Brocato N, Bruno MF, Araujio CE, Cervellino JC, Pirisi C, Tempereley G, Sparrow C, Savulsky C and Balbiani LR (1995) Treatment of non-small cell lung cancer with ifosfamide (IFO) + 4′-epiadriamycin (EPI) + platinum versus IFO + EPI: a GETLAC study. Oncology 52: 24-31
2. Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Sem in Oncol 23: 71-75
3. Crino' L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Meacci M, Corgna F, Darwish S, Scarcella L, Santucci A, Ballatori E and Tonato M (1995) Chemotherapy of advanced non-small cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 6: 347-353
4. Cullen MH (1993) Mitomycin C, ifosfamide, and cisplatin in non-small cell lung cancer. Oncology 50 (suppl. 1): 31-34
5. Depierre A, Chastang CL, Quoix E, Leheau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Mono D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal Celigny P, Badri N and Besenval M (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5: 37-12
6. De Marinis F, Nunziati F, Noseda MA, Signora M, Vaccarino M, Alma M, Pallotta G and Salvati F (1990) Epirubicin and ifosfamide in the treatment of NSCLC stage IIIB-IV. Ann Oncol 1 (suppl.): 62
7. Drings P, Djawid N, Bulzebruch H (1989) Chemotherapy of advanced non-small cell lung cancer with ifosfamide and vindesine. In Ifosfamide in the Treatment of Lung Cancer. Contribution to Oncology. Hossfeld DK (ed.), pp. 91-102. Karger: Basle.
8. Ettinger DS (1993) Overview of paclitaxel (Taxol) in advanced lung cancer. Sem Oncol 4 (suppl. 3): 46-49
9. Feld R, Wierzbicki R, Walde D (1990) Phase I-II study of high-dose epirubicin in advanced non-small cell lung cancer. J Clin Oncol 10: 297-303
10. Fufuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M and Kunusaki Y (1991) A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9: 606-613
11. Gebbia V, Caruso M, Valenza R, Testa A, Cannata G, Verderame F, Cipolla C, Curto G, Oliveri D, Chiarenza M, Latteri MA, Di Gesu and Gebbia N (1984) Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res 14: 1247-1250
12. Gehhia V, Galetta D, Maiello E, Valenza R, Colucci G and Gebbia N (1996) Treatment of stage III-IV non-small cell lung carcinoma with vinorelbine in combination with ifosfamide plus mesna: a study of the Southern Italy Oncology Group (GOIM). Am J Clin Oncol 19, 278-280
13. Goldie J, Coldman A and Gudauskas G (1982) Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Res 66: 439-449
14. Gridelli C, Rossi A, Incoronato P, Bruni GS, Scognamiglio F, Ruffolo P, Rinaldi L and Bianco AR (1996) Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 37: 613-615
15. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872
16. Grunberg SM, Crowley J, Livingston R, Gill I, Williamson SK, O'Rourke T, Braun T, Marschall ME, Weick JK, Balcerzak SP and Martino RL (1993) Fxtended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 11: 1598-1601
17. Hansen HH and Lund B (1994) Single agent therapy with gemcitabine in lung cancer - a review, Lung Cancer 11: 28-29
18. Johnson DH (1990) Chemotherapy for unresectable non-small cell lung cancer. Sem Oncol 17: 20-29
19. Joss RA, Hansen HH, Hansen M, Renards J and Rozencweig M (1984) Phase II trial of epirubicin in advanced squamous, adeno and large cell carcinoma of the lung. Eur J Clin Oncol 20: 495-499
20. Joss RA, Burki K, Dalquen P, Schatzmann E, Leyvraz S, Cavalli F, Ludwig C, Siegenthaler P, Alberto P, Stahel R, Holdener EE and Senn H (1990) Combination chemotherapy with mitomycin, vindesine, and cisplatin for non small cell lung cancer. Cancer 65: 2426-2434
21. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffle P, Panizo A. Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P and Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a Furopean multicenter trial including 612 patients. J Clin Oncol 12: 360-367
22. Lilenbaum RC and Green MR (1993) Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11: 1391-1402
23. Martoni A, Melotti B, Guaraldi M and Pannuti F (1991) Activity of high-dose epirubicin in advanced non-small cell lung cancer, Eur J Cancer 27: 1231-1234
24. Martoni A, Guaraldi M, Casadio M, Busutti I and Pannuti F (1992) A phase II study of high-dose epirubicin plus cisplatin in advanced non-small cell lung cancer (NSCLC). Ann Oncol 3: 864-866
25. Meyers FJ, Cardiff RD, Quadro R, Gribble M, Kohler M, Metrano U, Mitchell EP, Shiffman R and William L (1986) Epirubicin in non oat cell lung cancer - response rate and importance of immunopathology: a Northern California Oncology Group study. Cancer Treat Rep 70: 805-806
26. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
27. Miller AB, Chem TT, Coltman CA, O'Bryan RM, Vance RB, Weiss GB, Fletcher WS, Stephens RL and Livingston RB (1986) Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung: a Southwest Oncology Group Study. J Clin Oncol 4: 502-508
28. Non Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909
29. Norton L and Day R (1991) Potential innovations in scheduling of cancer chemotherapy. Import Adv Oncol 22: 57-72
30. Shepherd FA, Evans WK, Goss PE, Latreille J, Logan D, Maroun J, Steward D, Warner E and Paul K (1992) Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Sem Oncol 19: 54-58
31. Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25-32
32. Steward WP and Dunlop DJ (1995) New drugs in the treatment of non-small cell lung cancer. Ann Oncol 6 (suppl. 1): S49-S54
33. Thatcher N, Ranson M, Lee SM, Niven R and Andersen H (1995) Chemotherapy in non-small cell lung cancer. Ann Oncol 6 (suppl. 1): S83-S84
34. Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CA, Taylor SA and Livingston RB (1991) A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 7: 1157-1162
35. Wils J, Utama I, Sala L, Smeets J and Riva A (1990) Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer 26: 1140-1141